Indo Borax Q1 FY27: higher utilization lifts margins as the company reshapes its portfolio

Indo Borax and Chemicals Ltd. entered FY27 with a sharper profit profile and a clear set of corporate actions that could change the shape of the group over time. For the quarter ended June 30, 2026 (Q1 FY27), the company reported consolidated operating revenue of Rs. 70.36 Cr, up 31.34% year on year from Rs. 53.57 Cr. Profitability moved even faster. EBITDA rose 62.16% year on year to Rs. 19.80 Cr, and PAT increased 59.31% to Rs. 16.25 Cr, with EPS at Rs. 5.07.

The quarter is worth reading in two layers. The first is operational. The company attributed the performance to improved capacity utilization, operational efficiencies, and higher realizations, supported by steady domestic demand. The second is strategic. After the quarter, the Board approved a scheme to amalgamate its wholly owned subsidiary, Indoborax Infrastructure Private Limited, into Indo Borax and also approved the acquisition of a 64.26% stake in Kronox Lab Sciences. Put together, the results show a business that is benefiting from tighter execution in its core boron chemicals franchise while simultaneously preparing for a broader specialty chemicals footprint.

A strong quarter, driven by execution rather than a single lever

Indo Borax has a long operating history and a focused product position in India. Established in 1980, it is a leading player in boric acid with about 50% market share and is the sole manufacturer of IP grade boric acid in India with a valid FDA license and BIS license. That combination matters because it anchors the company in applications where quality and compliance are central, while still allowing scale in large industrial end markets.

In Q1 FY27, operating revenue moved from Rs. 53.57 Cr in Q1 FY26 to Rs. 70.36 Cr. The step up becomes more meaningful when seen alongside EBITDA, which expanded from Rs. 12.21 Cr to Rs. 19.80 Cr over the same period. Management highlighted higher capacity utilization and operational efficiencies as key drivers. That suggests the quarter was not simply about demand showing up but also about how well the facility ran and how effectively the company converted volumes into cash profits. The company also cited higher realizations, which typically indicates better pricing and product mix, and is often the difference between a good quarter and a structurally better quarter.

Net profit followed the same pattern. PAT rose from Rs. 10.20 Cr in Q1 FY26 to Rs. 16.25 Cr in Q1 FY27. In a commodity adjacent industry, sustained profit growth requires either an operating edge, a brand and quality edge, or integration benefits. Indo Borax points to all three: a premium brand built over decades, regulatory credentials in pharma grade boric acid, and forward integration into DOT.

The broader profitability picture from FY25 to FY26

The quarter sits on top of a year in which the company grew revenue but had a flatter EBITDA line. For FY26, consolidated operating revenue increased 22.9% year on year to Rs. 215.45 Cr from Rs. 175.26 Cr in FY25. PAT grew 18.3% year on year to Rs. 50.27 Cr, and EPS increased to Rs. 15.67.

EBITDA, however, was Rs. 44.16 Cr in FY26 versus Rs. 45.89 Cr in FY25. The presentation still characterizes profitability as healthy, and states an EBITDA margin of 20.5% and a PAT margin of 21.8% during FY26, while also noting that plant balancing initiatives improved capacity utilization and supported demand growth.

This backdrop makes Q1 FY27 important. A quarter where EBITDA accelerates and the margin is explicitly called out at 28.14% signals that the levers management highlighted are showing up in the financials. Investors will still want to see whether that margin level sustains over coming quarters, but the direction is clear: the company is trying to translate its leadership position in boric acid into a stronger earnings conversion.

Capacity, product positioning, and why boric acid still matters

Indo Borax runs a state of the art facility at Pithampur, Madhya Pradesh with in-house technology. It reports production capacity of 20,000 MTPA for boric acid and 6,000 MTPA for Disodium Octaborate Tetrahydrate (DOT). Scale alone is not the full story. The company also emphasizes its established customer and distributor relationships, built across decades, and its status as a premium brand.

The market context supports a constructive demand view. The presentation notes that steel and refractory applications contribute about 55% to 60% of boric acid demand, linking the product to India’s broader infrastructure and industrial growth. It also estimates that India’s boric acid market could grow at a CAGR of 7% to 8% from FY26 to FY30, with total demand rising from 38 to 40 thousand tons in FY26 to 50 to 53 thousand tons by FY30.

Within that market, the company positions itself as well placed to capture incremental demand and is evaluating downstream expansion and debottlenecking opportunities. The phrasing matters. Debottlenecking is usually a lower risk path to higher output because it targets constraints in an existing line rather than building a new plant from scratch. Downstream expansion can also strengthen realizations by shifting mix toward higher value derivatives.

End use mix further explains why the product can be relatively resilient. The presentation provides an end use split by volume: steel at 55% to 60%, plywood at 10% to 15%, personal care and home care at 10%, pharma at 5% to 10%, ceramics and tiles at 5%, and others including insecticides and pesticides at 10%. That spread reduces dependence on a single end market, even though steel remains the anchor.

DOT integration and what it says about margin intent

A key strategic pillar in the presentation is forward integration into DOT. DOT is described as a value added agriculture boron micronutrient fertilizer, and also has industrial uses such as fire retardancy and as an additive in cleaning products. The company notes that DOT is mainly imported from Turkey, USA, Peru, and Argentina, and that Indo Borax has a license to produce DOT and has set up a plant at Pithampur with capacity of 6,000 MTPA.

What stands out is the margin logic. Boric acid is a key raw material for producing DOT, and the company’s in-house boric acid supply enables higher margins versus other players. The stated go-to-market approach includes tying up with fertilizer companies and competing on import parity price and quality.

This integration is not just an add-on product. It is a way to move up the value chain while reducing exposure to pure boric acid pricing cycles. If executed well, DOT can also widen the company’s relevance beyond industrial customers into agriculture led distribution systems. That can diversify demand drivers, which is especially important when steel demand, while large, can be cyclical.

Management’s tone: discipline, consolidation, and a bigger platform

In the management commentary, Managing Director and CEO Suresh Kalra framed Q1 FY27 as a product of higher capacity utilization, better realizations, strategic expansion initiatives, and steady domestic demand. He also highlighted fiscal discipline, operational excellence, and value creation, and said the company maintained healthy profitability and a strong balance sheet.

Two board decisions after the quarter bring that operating narrative into a corporate structure narrative.

First, Indo Borax approved the scheme of amalgamation of its wholly owned subsidiary, Indoborax Infrastructure Private Limited, with the listed entity. The stated intent is greater efficiency, more effective utilization of combined resources, more concentrated management focus, streamlined governance, and faster decision making. For investors, such moves are often less about immediate earnings and more about reducing complexity, improving capital allocation, and making the group easier to evaluate.

Second, the company approved the acquisition of 64.26% equity shares of Vadodara headquartered listed specialty chemicals player Kronox Lab Sciences. As per the share purchase agreement, Indo Borax will acquire 2,38,44,000 equity shares for an aggregate consideration of Rs 246.12 Cr. The Board also approved making an open offer along with Zenrock Chemicals Limited as a person acting in concert, for acquisition of up to 95,70,000 equity shares of Kronox Lab Sciences, representing a 25.79% stake.

The strategic rationale offered in the presentation is centered on using Kronox’s experience and export presence to strengthen offerings and improve margins through synergies. Kronox is described as bringing 185+ specialty chemical products, export presence, and FY26 revenue and PAT of about Rs 101 Cr and about Rs 28 Cr. The acquisition is expected to support premiumisation, diversification, and margin improvement.

While the presentation does not provide pro forma combined numbers, the logic aligns with Indo Borax’s broader positioning. The company already has leadership and compliance credentials in boron based chemicals. Adding a specialty chemicals platform with exports can broaden market access and reduce dependence on any one domestic cycle. But it also introduces integration execution risk, and investors will likely watch how the company balances its core boron franchise with a wider product footprint.

Governance and leadership as part of the investment case

Indo Borax emphasizes a robust board and a refreshed leadership team. The company notes that ownership transfer concluded with transfer of 50.80% promoter stake to institutional investors in January 2026, and that a new leadership team was onboarded.

The board profiles in the presentation highlight operating depth and governance experience. The Managing Director and CEO, Suresh Kalra, brings over 28 years in chemical industry leadership across India, the US, the Middle East, and Asia Pacific, with roles across multiple global companies. The presentation also profiles an Executive Director with experience in global operations and financial performance initiatives, and a Non-Executive Director with long entrepreneurial experience.

Independent directors bring backgrounds in banking leadership, specialty chemicals leadership, and senior government administration with environmental and policy experience. For a manufacturing and chemicals company, that mix can matter for capital discipline, risk management, compliance, and project evaluation.

What investors should take away

Q1 FY27 sets a clear theme: disciplined execution is improving earnings quality, and the company is using that momentum to simplify its structure and broaden its portfolio. The quarter’s revenue growth of 31.34% and EBITDA growth of 62.16% suggest that utilization and realizations are combining in Indo Borax’s favor. PAT growth of 59.31% further confirms that the operational gains are reaching the bottom line.

At the business level, Indo Borax remains a focused leader in boric acid with about 50% market share, regulatory credentials in IP grade production, and meaningful installed capacity at Pithampur. The stated market outlook for boric acid in India, with demand rising from 38 to 40 thousand tons in FY26 to 50 to 53 thousand tons by FY30, supports a growth runway. DOT integration provides another pathway to protect margins and expand into agriculture linked demand.

At the corporate level, the amalgamation of the wholly owned subsidiary points to a cleaner structure. The Kronox acquisition points to a larger ambition: using a specialty chemicals platform and exports to drive premiumisation and diversification. If management can sustain the execution seen in Q1 FY27 while integrating new assets carefully, the company’s story can shift from being a category leader in a single chemical to a broader, more resilient chemicals group.